Past issues are only available to subscribers. If you are not a member, click here to join.

February 2015PDF

 Lymphoma

Gazyva Increases PFS in Phase III Trial Of Indolent Non-Hodgkin’s Lymphoma Patients

Patients with indolent non-Hodgkin’s lymphoma lived significantly longer without disease worsening or death when treated with Gazyva (obinutuzumab) plus bendamustine and followed by Gazyva alone, compared to bendamustine alone. 

The phase III trial was stopped by an independent data monitoring committee following a pre-planned interim analysis due to the level of benefit seen in the Gazyva arm compared to the bendamustine arm. The study’s primary endpoint was progression-free survival. There were no unexpected adverse events with Gazyva.

 Leukemia

Imbruvica Demonstrates 88% Response Rate In Studies of Relapsed/Refractory CLL Patients

Two independent phase III clinical trials, LUX-Lung 3 and LUX-Lung 6, in epidermal growth factor receptor mutation-positive metastatic non-small cell lung cancer demonstrated positive results in overall survival.

In each trial, patients whose tumors have the most common EGFR mutation—deletion in exon 19—lived more than one year longer when treated with first-line afatinib (Gilotrif) compared to standard chemotherapy. The data was published in The Lancet Oncology.

 Drugs and Targets

FDA Grants Accelerated Approval to Ibrance In HER2-Negative Metastatic Breast Cancer

FDA granted accelerated approval to Ibrance (palbociclib) to treat metastatic breast cancer.

Ibrance inhibits cyclin-dependent kinases 4 and 6, which are involved in promoting the growth of cancer cells. Ibrance is intended for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who have not yet received an endocrine-based therapy. It is to be used in combination with letrozole.

Also: FDA approves Lenvima, expands label for Revlimid, and more

 Prostate Cancer
Researchers: Cabazitaxel Functions Differently Than Other Taxanes
 Childhood Cancer
Cranial Irradiation Can Increase Risk of Pituitary Hormone Deficiencies Later in Life, Study Says
 Imaging
Study: Lymphoseek Patients Had Fewer Sentinel Lymph Nodes Removed Per Procedure
 Head and Neck Cancers
TCGA Researchers Discover Genomic Differences in Cancers Caused by Infection
 NCI CTEP-Approved Trials for the Month of February
20150226 - Feb. 26, 2015
ISSUE 7 – FEB. 20, 2015PDF

Fix MD Anderson’s Woes, Faculty Urges UT System

The Faculty Senate of MD Anderson Cancer Center asked UT System officials and the Board of Regents to “provide guidance” to the administration of the Houston-based center “in establishing milestones and timelines to implement measures to improve the morale of the faculty and the general health of the Institution.”

The resolution, which was distributed to faculty Feb. 16, reveals that the faculty’s dissatisfaction with MD Anderson President Ronald DePinho continues even after top UT System officials put him on notice to improve the faculty’s morale (The Cancer Letter, Nov. 7, 2014). 

ASCO’s Multi-Million Big Data Project Aspires to be the “Bedrock” of Oncology

The CancerLinQ database of electronic health records is going through testing at 15 practices, and will be made available for research projects later this year.

The database, launched and operated by the American Society of Clinical Oncology, was designed to pool millions of physician and patient records from practices and hospitals.

Conversation with The Cancer Letter

ASCO CEO Allen Lichter Discusses CancerLinQ

Five years into the making of CancerLinQ, the American Society of Clinical Oncology is poised to become the next big player in oncology bioinformatics.

ASCO has enlisted the help of SAP, a large multinational corporation that specializes in enterprise software, to structure over 170,000 electronic medical records into a growing database that will be launched later this year.

Billed as a “physicians for physicians” product, CancerLinQ is expected to yield high quality data that only quality research proposals can access. 

Funding Opportunity

PhRMA Launches Web Portal For Competitive Grants

The Pharmaceutical Research and Manufacturers of American Foundation launched a platform featuring resources on its competitive research grants and fellowships for young scientists.

The foundation awards more than $3.3 million annually to researchers with support from PhRMA’s member companies. Recent grants have focused on topics such as comparative effectiveness, adherence improvement and health outcomes.

In Brief

  • Theodore Lawrence named director of University of Michigan Cancer Center

  • Karen Knudsen named interim director of Sidney Kimmel Cancer Center

  • Jonathan Jarow named acting director of FDA’s Office of Medical Policy

  • AACR names class of 11 AACR Academy fellows

  • Varian Medical Systems selected to build proton therapy center in Denmark

Drugs and Targets

  • FDA approves Lenvima in thyroid cancer

  • FDA expands indication for Revlimid to include multiple myeloma

  • Orphan Drug Designation granted to Saposin C

  • FDA grants Orphan Drug Designation to Reolysin in pancreatic cancer

  • FDA grants Orphan Drug Designation to doxorubicin formulation

  • NHS establishes access program for Oncotype DX

20150220 - Feb. 20, 2015
SPECIAL REPORT – FEB. 17, 2015 


Faculty Urges UT System to Help Fix MD Anderson’s Woes

The Faculty Senate of MD Anderson Cancer Center asked the UT System officials and the Board of Regents to “provide guidance” to the administration of the Houston-based center “in establishing milestones and timelines to implement measures to improve the morale of the faculty and the general health of the Institution.”

The resolution, which was distributed to the faculty on Feb. 16, reveals that the faculty’s dissatisfaction with MD Anderson President Ronald DePinho continues even after top UT System officials put him on notice to improve the faculty’s morale (The Cancer Letter, Nov. 7, 2014).

20150217 - Feb. 17, 2015